Abstract
Urinary polyamine (UPA) excretion patterns were measured in 39 patients with clinically evaluable epithelial ovarian cancer immediately before they were treated with a cycle of chemotherapy and 24-48 h after chemotherapy to ascertain if changes in UPA excretion patterns correlated with eventual response to treatment. Almost all of the 19 patients who responded to chemotherapy had a rise in the excretion of all UPA fractions after treatment while most patients with chemoresistant cancer showed only an increase in the excretion of the putrescine and spermine fractions. However, a two-fold increase in excretion of the spermidine fractions occurred exclusively in patients who would eventually respond to chemotherapy. This phenomenon was not seen in patients with chemoresistant cancer. If, 48 h after chemotherapy, a patient with epithelial ovarian cancer does not show at least a doubling of the urinary levels of spermidine, acetylspermidine or total polyamine excretion that chemotherapy should be stopped since it is unlikely to be effective.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bradley E. C., Issell B. F., Hellman R. The human tumor colony-forming chemosensitivity assay: a biological and clinical review. Invest New Drugs. 1984;2(1):59–70. doi: 10.1007/BF00173788. [DOI] [PubMed] [Google Scholar]
- Durie B. G., Salmon S. E., Russell D. H. Polyamines as markers of response and disease activity in cancer chemotherapy. Cancer Res. 1977 Jan;37(1):214–221. [PubMed] [Google Scholar]
- Horn Y., Beal S. L., Walach N., Lubich W. P., Spigel L., Marton L. J. Relationship of urinary polyamines to tumor activity and tumor volume in patients. Cancer Res. 1984 Oct;44(10):4675–4678. [PubMed] [Google Scholar]
- Kingsnorth A. N., Wallace H. M. Elevation of monoacetylated polyamines in human breast cancers. Eur J Cancer Clin Oncol. 1985 Sep;21(9):1057–1062. doi: 10.1016/0277-5379(85)90291-3. [DOI] [PubMed] [Google Scholar]
- Lawton F. G., Redman C. W., Luesley D. M., Chan K. K., Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol. 1989 Jan;73(1):61–65. [PubMed] [Google Scholar]
- Lawton F., Griffin M., Slack J., Blackledge G. Urinary polyamine excretion patterns in patients with epithelial ovarian cancer. Gynecol Obstet Invest. 1989;28(4):212–214. doi: 10.1159/000293581. [DOI] [PubMed] [Google Scholar]
- Richardson G. S., Scully R. E., Nikrui N., Nelson J. H., Jr Common epithelial cancer of the ovary (2). N Engl J Med. 1985 Feb 21;312(8):474–483. doi: 10.1056/NEJM198502213120804. [DOI] [PubMed] [Google Scholar]
- Russell D. H., Durie B. G., Salmon S. E. Polyamines as predictors of success and failure in cancer chemotherapy. Lancet. 1975 Oct 25;2(7939):797–799. doi: 10.1016/s0140-6736(75)80009-2. [DOI] [PubMed] [Google Scholar]
- Woo K. B., Waalkes T. P., Abeloff M. D., Lenhard R. E., Jr, Gehrke C. W., Kuo K. C. Urinary polyamines for evaluating the course of disease for patients with small cell carcinoma of the lung. Cancer. 1983 Nov 1;52(9):1684–1690. doi: 10.1002/1097-0142(19831101)52:9<1684::aid-cncr2820520923>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]